World-renowned expert in psychopharmacology, addiction, and mental health treatments joins the fast-growing neuroscience company to help advance pioneering therapeutics BOSTON, Oct. 25, 2021 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the appointment of…


Previous articleMindMed CMO to Chair Digital Biomarkers Summit
Next articleMindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program